본문으로 바로가기
Product Thumnail Image
Product Thumnail Image
Product Thumnail Image
Product Thumnail Image

ACCEL ELISA COVID19 TEST KIT

By ACCEL ELISA COVID19 test kit

Negotiable | Min. Order

Description
ACCEL ELISA® COVID-19 Total Antibody Kit This test kit is a serology-based SARS-CoV-2 total antibody detection assay which utilizes Plexense’s proven and patented ACCEL ELISA® technology for sensitive, rapid and accurate results. The ACCEL ELISA® COVID-19 assay uses the SARS-CoV-2 nucleocapsid protein (N-protein) developed by the BioNano Health Guard Research Center (a division of the Ministry of Science and ICT, Korea) in collaboration with Korea Research Institute of Bioscience and Biotechnology (KRIBB) for the sole use of COVID-19 antibody detection on ACCEL ELISA® platform.
Place of Origin
South Korea

Size
158.0 * 93.0 * 103.0 mm
Weight
700 g
Payment Terms
T/T
TKPAY Sample
Samples INFO

Negotiable | (Min. Order)

Payment
  • visa
  • master
  • jcb
  • unionPay
  • 1 Plexense

    Supplier Activity

    Country South Korea South Korea

    KITA DUNS

    Send Message
    PRODUCT DESCRIPTION
    COMPANY INFORMATION
    Product Information

    ACCEL ELISA® COVID-19 Total Antibody Kit

     

    This test kit is a serology-based SARS-CoV-2 total antibody detection assay which utilizes Plexense’s proven and patented ACCEL ELISA® technology for sensitive, rapid and accurate results.

     

    The ACCEL ELISA® COVID-19 assay uses the SARS-CoV-2 nucleocapsid protein (N-protein) developed by the BioNano Health Guard Research Center (a division of the Ministry of Science and ICT, Korea) in collaboration with Korea Research Institute of Bioscience and Biotechnology (KRIBB) for the sole use of COVID-19 antibody detection on ACCEL ELISA® platform.

     

    Image
    • KakaoTalk_20201030_181827231_03

    • KakaoTalk_20201030_181827231_02

    • KakaoTalk_20201030_181827231_01

    Feature

    The ACCEL ELISA® has greatly simplified the tedious process of conventional ELISA test method through its patented well-design technology. Now, laboratories and test centers worldwide have the option of selecting and deploying ELISA tests across all their facilities without the need for exotic equipment. Each ACCEL ELISA® COVID-19 kit can test up to 94 patient samples simultaneously in just under 45 minutes.  In terms of daily testing capacity, ramping up to 3,000 or even 10,000 tests per day is as simple as adding clinical staff and basic laboratory instruments.  It is that simple and quick, and all possible due to the new ACCEL ELISA® technology. 

     

    In terms of accuracy, ACCEL ELISA® COVID-19 Kit has a 98.5% overall agreement to real time PCR testing method.  At the heart of Plexense’s ACCEL ELISA® technology is the precision-cut “starburst” design. This was designed with the intent to improve antibody capture from any angle within the well and optimize surface chemistry for higher sensitivity and better performance.  Based on recent clinical assessment of 341 patient samples shows that the ACCEL ELISA® COVID-19 Kit performed at a sensitivity of 100% and a specificity of 100% for patients with 5 or more days onset of infection. 

    Spec

    Why choose ACCEL ELISA® over other platforms? 

     

    ·Quick testing turnaround for the detection of total antibodies (IgA, IgM, IgG) against SARS-Cov-2 antigens 

    ·Highly improved sensitivity over lateral flow (immunochromatography) method 

    ·High-throughput testing available up to 94 patient samples at a single run ·96-well strip plate formatted 

    ·Compatible with standard plate reader (OD read at 650nm) 

    ·Sample type & volume required per well: 10 μL human blood serum 

    ·30 minutes Assay time 

    ·Validation of assay with 341 patient sera samples confirmed high accuracy results –Sensitivity 94.4%, Specificity 100%, Overall Agreement with RT-PCR 98.5%

    Company
    Plexense

    Plexense

    Country South Korea South Korea

    Supplier Activity

    President
    KIM GI BEOM
    Address
    670, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
    Product Category
    Medical Test Kit
    Year Established
    2012
    No. of Total Employees
    1-50
    Company introduction

    We are Plexense Inc., a South Korean company that specializes in the development and production of a fast and cost-effective Elisa immunoassay platform for clinical, food and life science testing. We are providers of a serology based diagnostic kits for the Covid-19. The only Korean serology-based product supported and endorsed by the Korean Ministry of Science and Technology.

     

    Our main product is Covid-19 kit which is an advanced ELISA platform that is very cost effective, patented technology that makes the accuracy of our product excellent.

    If you are interested in our kit for the Covid-19, please visit our website: www.plexense.com

    Main Markets
    • Brazil Brazil ,
    • Canada Canada ,
    • Colombia Colombia ,
    • Indonesia Indonesia ,
    • India India ,
    • Philippines Philippines ,
    • Pakistan Pakistan ,
    • U.S.A U.S.A ,
    • South Africa South Africa

    Other Products viewed with This Product